Furthermore, it has been predicted that levosimendan, a heart failure drug, could serve as a potential inhibitor of several kinases including RIO Kinase 1 (RIOK1), through ligand-binding site comparison and protein-ligand docking. Here, RIOK1 is linked to heart failure.